×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Germany | MorphoSys | Constellation

German Biotech Company MorphoSys Buys US Rival for $1.7B

Wednesday, 02 June 2021 10:00 AM

BERLIN (AP) — Germany-based MorphoSys AG said Wednesday that it is buying U.S. rival Constellation Pharmaceuticals Inc. in a deal valuing the biotech company at $1.7 billion.

MorphoSys said in a statement that it has agreed to pay $34 in cash per Constellation share and the takeover has been unanimously approved by both companies' boards.

Constellation, based in Cambridge, Mass., specialized in novel therapeutics in patients with cancer.

The deal, expected to be completed in the third quarter, was enabled through $2.025 billion in funding that MorphoSys received from investor Royalty Pharma, in return for royalties on several drugs developed by the German company, which is headquartered in Planegg near Munich.

© Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


GlobalTalk
Germany-based MorphoSys AG said Wednesday that it is buying U.S. rival Constellation Pharmaceuticals Inc. in a deal valuing the biotech company at $1.7 billion.MorphoSys said in a statement that it has agreed to pay $34 in cash per Constellation share and the takeover has...
Germany,MorphoSys,Constellation
110
2021-00-02
Wednesday, 02 June 2021 10:00 AM
Newsmax Media, Inc.
More Articles
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved